UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

Clinical pharmacology and therapeutics, 2009-10, Vol.86 (4), p.396-402

2009

Volltextzugriff (PDF)

Interaction of Cisplatin with the Human Organic Cation Transporter 2

Clinical cancer research, 2008-06, Vol.14 (12), p.3875-3880

2008

Volltextzugriff (PDF)

Interaction of Imatinib with Human Organic Ion Carriers

Clinical cancer research, 2008-05, Vol.14 (10), p.3141-3148

2008

Volltextzugriff (PDF)

Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report

JNCI : Journal of the National Cancer Institute, 2022-04, Vol.114 (4), p.489-495

2022

Volltextzugriff (PDF)

Pharmacogenomics in oncology care

Frontiers in genetics, 2014-04, Vol.5, p.73-73

2014

Volltextzugriff (PDF)

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

Clinical cancer research, 2010-10, Vol.16 (19), p.4789-4799

2010

Volltextzugriff (PDF)

Updating the landscape of direct-to-consumer pharmacogenomic testing

Pharmacogenomics and personalized medicine, 2017-01, Vol.10, p.229-232

2017

Volltextzugriff (PDF)

Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration

BMC medical informatics and decision making, 2017-05, Vol.17 (1), p.71-71, Article 71

2017

Volltextzugriff (PDF)

Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes

Cancer epidemiology, biomarkers & prevention, 2022-03, Vol.31 (3), p.495-506

2022

Volltextzugriff (PDF)

Palliative Intent Treatment and Palliative Care Delivery for Individuals With Advanced Nonsmall Cell Lung Cancer and Melanoma: A Patterns of Care Study

Journal of palliative medicine, 2024-03, Vol.27 (3), p.316

2024

Volltextzugriff (PDF)

Epidemiologic Research of Rare Cancers: Trends, Resources, and Challenges

Cancer epidemiology, biomarkers & prevention, 2021-07, Vol.30 (7), p.1305-1311

2021

Volltextzugriff (PDF)

Pre-neuronal acetylcholine: Non-neuronal cholinergic cells communicate to sensory neurons

Autonomic neuroscience, 2013-08, Vol.177 (1), p.31-31

2013

Volltextzugriff (PDF)

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients

Journal of managed care & specialty pharmacy, 2020-12, Vol.26 (12), p.1494

2020

Volltextzugriff (PDF)

Dosing recommendations for pharmacogenetic interactions related to drug metabolism

Pharmacogenetics and genomics, 2016-07, Vol.26 (7), p.334-339

2016

Volltextzugriff (PDF)

Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase

Clinical cancer research, 2010-08, Vol.16 (16), p.4198-4206

2010

Volltextzugriff (PDF)

Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine

Pharmacoepidemiology and drug safety, 2021-08, Vol.30 (8), p.985-992

2021

Volltextzugriff (PDF)

Cholinergic chemosensory brush cells in the urethra

Autonomic neuroscience, 2013-08, Vol.177 (1), p.60-61

2013

Volltextzugriff (PDF)

Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop

Cancer epidemiology, biomarkers & prevention, 2015-09, Vol.24 (9), p.1427-1433

2015

Volltextzugriff (PDF)

P01.16.B Neurocognitive outcome and seizure freedom after awake surgery of gliomas

Neuro-oncology (Charlottesville, Va.), 2022-09, Vol.24 (Supplement_2), p.ii27-ii27

2022

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs

Clinical lung cancer, 2017-07, Vol.18 (4), p.401-409

2017

Volltextzugriff (PDF)

BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines

Familial cancer, 2017, Vol.16 (1), p.41-49

2017

Volltextzugriff (PDF)

An overview of recommendations and translational milestones for genomic tests in cancer

Genetics in medicine, 2015-06, Vol.17 (6), p.431-440

2015

Volltextzugriff (PDF)

P14.11 Severe treatment-induced myelosuppression is more frequent in female malignant glioma patients and associated with reduced overall survival

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii39-ii40

2021

Volltextzugriff (PDF)

Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies

PLoS currents, 2014, Vol.6

2014

Volltextzugriff (PDF)

An efficient synthesis of 2-(3-(4-amidinophenylcarbamoyl)naphthalen-2-yl)-5-((2,2-methylpropyl)carbamoyl)benzoic acid: a factor VIIa inhibitor discovered by the Ono Pharmaceutical Company

Tetrahedron letters, 2000, Vol.41 (32), p.6041-6044

2000

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(78)
Dissertationen
(1)

Sprache

Englisch
(79)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(58)
Animals
(30)
Humans
(24)
Biological And Medical Sciences
(20)
Medical Sciences
(15)
Male
(13)
Mice
(13)
Oncology
(13)
Biochemistry & Molecular Biology
(12)
Pharmacology & Pharmacy
(12)
Public, Environmental & Occupational Health
(9)
Genetics & Heredity
(8)
Female
(7)
Infectious Diseases
(7)
Pharmacology. Drug Treatments
(7)
Tropical Medicine
(7)
Chemistry, Medicinal
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Infections
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

Interaction of Cisplatin with the Human Organic Cation Transporter 2

Interaction of Imatinib with Human Organic Ion Carriers

Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report

Pharmacogenomics in oncology care

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

Updating the landscape of direct-to-consumer pharmacogenomic testing

Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration

Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes

Palliative Intent Treatment and Palliative Care Delivery for Individuals With Advanced Nonsmall Cell Lung Cancer and Melanoma: A Patterns of Care Study

Epidemiologic Research of Rare Cancers: Trends, Resources, and Challenges

Pre-neuronal acetylcholine: Non-neuronal cholinergic cells communicate to sensory neurons

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients

Dosing recommendations for pharmacogenetic interactions related to drug metabolism

Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase

Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine

Cholinergic chemosensory brush cells in the urethra

Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop

P01.16.B Neurocognitive outcome and seizure freedom after awake surgery of gliomas

Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs

BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines

An overview of recommendations and translational milestones for genomic tests in cancer

P14.11 Severe treatment-induced myelosuppression is more frequent in female malignant glioma patients and associated with reduced overall survival

Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies

An efficient synthesis of 2-(3-(4-amidinophenylcarbamoyl)naphthalen-2-yl)-5-((2,2-methylpropyl)carbamoyl)benzoic acid: a factor VIIa inhibitor discovered by the Ono Pharmaceutical Company

Suchergebnisse filtern